TrialJournal of gynecologic oncology2025

Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.

Yidong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.